Literature DB >> 22542703

Intercostal neuroma as a source of pain after aesthetic and reconstructive breast implant surgery.

John T Nguyen1, Ian A Buchanan, Priti P Patel, Nika Aljinovic, Bernard T Lee.   

Abstract

The development of persistent post-operative pain after implant placement for aesthetic or reconstructive breast surgery can lead to significant patient morbidity. Although there are many etiologies for post-operative pain, the diagnosis of an intercostal neuroma is important as this can be treated surgically. We describe three cases of an intercostal neuroma in patients with breast implants. A Tinel's sign can be elicited along the lateral chest wall and a local anesthetic block temporarily alleviates this pain. Surgical management with identification and clipping of the intercostal neuroma and burying into the underlying muscle significantly decreases post-operative pain long term. In patients with persistent pain after breast implant placement, plastic surgeons must be aware of this treatable cause of pain.
Copyright © 2012 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22542703     DOI: 10.1016/j.bjps.2012.04.003

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  2 in total

1.  Post-mastectomy and post-breast conservation surgery pain syndrome: a review of etiologies, risk prediction, and trends in management.

Authors:  Victor E Chen; Benjamin A Greenberger; Zheng Shi; Shefali Gajjar; Wenyin Shi; Waleed F Mourad; Weisi Yan
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

2.  Predictive value of a diagnostic block in focal nerve injury with neuropathic pain when surgery is considered.

Authors:  Martijn J A Malessy; Ralph de Boer; Ildefonso Muñoz Romero; Job L A Eekhof; Erik W van Zwet; Michel Kliot; Albert Dahan; Willem Pondaag
Journal:  PLoS One       Date:  2018-09-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.